Comments
Drug major Sun Pharma on Wednesday said its Japanese subsidiary has launched its speciality product Ilumya, indicated for the treatment of plaque psoriasis in adult patients in Japan.
In June this year, Sun Pharma said its subsidiary had got approval from the Japanese government for Ilumya.
Related Stories
Sun Pharma Advanced Research gains over 3% on pact with Tripoint Therapeutics
In a regulatory filing, Sun Pharmaceutical Industries said its “wholly-owned Japanese subsidiary has launched Ilumya Subcutaneous Injection 100 mg Syringe in Japan for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies“.
Shares of Sun Pharma has risen 2 per cent higher in early deals and is currently trading 0.34 per cent higher at ₹512.20 apiece on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.